tirzepatide in osa Diabetes & Weight Loss Drug Now Approved for (Obstructive Sleep Apnea) Tirzepatide on obstructive sleep apnea-related

Patients with renal or hepatic impairment may be at higher risk of hypoglycemia

Gastrointestinal: The adverse effects most frequently reported and most associated with discontinuation of semaglutide include nausea, vomiting, abdominal pain, constipation, and diarrhea

For reference, the rate of discontinuation in the semaglutide study referenced above was 4.5% around half the rate of orforglipron with a longer trial period

doi: 10.1016/j.neubiorev.2024.105756

The clinical community closely observes the comparative data emerging from studies on retatrutide, tirzepatide, and semaglutide

Data may be made available through the corresponding author upon reasonable request and with permission of Carelon Research